Benzodiazepines for the relief of breathlessness in malignant and advanced non‐malignant diseases in adults
Referencias
Additional references
American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Journal of Respiratory and Critical Care Medicine 1999;159:321‐40.
Bausewein C, Booth S, Gysels M, Higginson IJ. Non‐pharmacological interventions for breathlessness in advanced stages of malignant and non‐malignant diseases. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD005623.pub2]
Beach D, Schwartzstein RM. The genesis of breathlessness ‐ What do we understand?. Booth S, Dudgeon D (Eds): Dyspnoea in advanced disease ‐ a guide to clinical management. First Edition. Oxford University Press, Oxford, 2006:1‐18.
Booth S, Dudgeon D. Dyspnoea in advanced disease ‐ a guide to clinical management. First Edition. Oxford University Press, Oxford, 2006.
Booth S, Moosavi SH, Higginson IJ. The etiology and management of intractable breathlessness in patients with advanced cancer: a systematic review of pharmacological therapy. Nature Clinical Practice Oncology 2008;5:90‐100.
Bruera E, Higginson IJ, Robb SD, von Gunten CF. Textbook of Palliative Medicine. First Edition. Hodder Arnold, London, 2006.
Davis C. Drug therapies. Ahmedzai SH, Muers MF (eds): Supportive Care in Respiratory Disease. First Edition. Oxford University Press, Oxford, 2005:147‐63.
Edwards A, Hood K, Matthews E, Russell D, Russell I, Barker J, et al. The effectiveness of one‐to‐one risk communication interventions in health care: a systematic review. Medical Decision Making 2000;20:290‐7.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD (2007). Download 31.01.2008. Available from: http://www.goldcopd.org.
Hardman JG, Limbird LE. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th Edition. McGraw‐Hill, New York, 2005.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.0. The Cochrane Collaboration. Available from www.cochrane‐handbook.org, 2008 [updated February 2008].
Higginson IJ, Addington‐Hall J. The epidemiology of death and symptoms. Doyle D, Hanks G, Cherny N, Calman K (eds): Oxford Textbook of Palliative Medicine. Third Edition. Oxford University Press, Oxford, 2004:14‐24.
Jennings AL, Davies AN, Higgins JP, Broadley K. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD002066]
Manning HL, Schwartzstein RM. Pathophysiology of dyspnea. New England Medical Journal 1995;333:1547‐53.
Muers MF, Round CE. Palliation of symptoms in non‐small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group. Thorax 1993;48:339‐43.
Neuman A, Gunnbjornsdottir M, Tunsater A, Nystrom L, Franklin KA, Norrman E, et al. Dyspnea in relation to symptoms of anxiety and depression: A prospective population study. Respiratory Medicine 2006;100:1843‐9.
Nordgren L, Sorensen S. Symptoms experienced in the last six months of life in patients with end‐stage heart failure. European Journal of Cardiovascular Nursing 2003;2:213‐7.
Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. Journal of Pain and Symptom Management 2006;31:58‐69.
Uronis HE, Abernethy AP. Oxygen for relief of dyspnea: what is the evidence?. Current Opinion in Supportive and Palliative Care 2008;2(2):89‐94.
